Sara Valdeolivas - Search Results

Year	Number of Results
2011	1
2012	2
2014	1
2015	1
2016	3
2017	2
2024	0

1

Prospects for cannabinoid therapies in basal ganglia disorders.

Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Fernández-Ruiz J, et al. Among authors: valdeolivas s. Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x. Br J Pharmacol. 2011. PMID: 21545415 Free PMC article. Review.

2

Cannabinoids: novel medicines for the treatment of Huntington's disease.

Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Sagredo O, et al. Among authors: valdeolivas s. Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):41-8. doi: 10.2174/157488912798842278. Recent Pat CNS Drug Discov. 2012. PMID: 22280340 Review.

3

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J. López-Sendón Moreno JL, et al. Among authors: valdeolivas s. J Neurol. 2016 Jul;263(7):1390-400. doi: 10.1007/s00415-016-8145-9. Epub 2016 May 9. J Neurol. 2016. PMID: 27159993 Clinical Trial.

4

Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.

Rodríguez-Cueto C, Hernández-Gálvez M, Hillard CJ, Maciel P, Valdeolivas S, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. Rodríguez-Cueto C, et al. Among authors: valdeolivas s. PLoS One. 2017 Apr 27;12(4):e0176521. doi: 10.1371/journal.pone.0176521. eCollection 2017. PLoS One. 2017. PMID: 28448548 Free PMC article.

5

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Valdeolivas S, et al. Neurotherapeutics. 2015 Jan;12(1):185-99. doi: 10.1007/s13311-014-0304-z. Neurotherapeutics. 2015. PMID: 25252936 Free PMC article.

6

Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome.

Rubio M, Valdeolivas S, Piscitelli F, Verde R, Satta V, Barroso E, Montolio M, Aras LM, Di Marzo V, Sagredo O, Fernández-Ruiz J. Rubio M, et al. Among authors: valdeolivas s. Pharmacol Res Perspect. 2016 Mar 5;4(2):e00220. doi: 10.1002/prp2.220. eCollection 2016 Apr. Pharmacol Res Perspect. 2016. PMID: 27069631 Free PMC article.

7

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.

Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz J. Valdeolivas S, et al. Int J Mol Sci. 2017 Mar 23;18(4):684. doi: 10.3390/ijms18040684. Int J Mol Sci. 2017. PMID: 28333097 Free PMC article.

8

Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.

Ooms M, Rietjens R, Rangarajan JR, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernandez-Ruiz J, Bormans G, Van Laere K, Casteels C. Ooms M, et al. Among authors: valdeolivas s. Neurobiol Aging. 2014 Dec;35(12):2858-2869. doi: 10.1016/j.neurobiolaging.2014.06.010. Epub 2014 Jun 16. Neurobiol Aging. 2014. PMID: 25018107

9

Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3.

Rodríguez-Cueto C, Hernández-Gálvez M, Hillard CJ, Maciel P, García-García L, Valdeolivas S, Pozo MA, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. Rodríguez-Cueto C, et al. Among authors: valdeolivas s. Neuroscience. 2016 Dec 17;339:191-209. doi: 10.1016/j.neuroscience.2016.09.046. Epub 2016 Oct 4. Neuroscience. 2016. PMID: 27717809

10

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Valdeolivas S, et al. ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9. ACS Chem Neurosci. 2012. PMID: 22860209 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

10 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year